Skip to content

The effect of hydromorphinone for continuous adductor canal block on postoperative analgesia and early rehabilitation in patients undergoing total knee arthroplasty

The effect of hydromorphinone for continuous adductor canal block on postoperative analgesia and early rehabilitation in patients undergoing total knee arthroplasty

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500107456
Enrollment
Unknown
Registered
2025-08-12
Start date
2025-09-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total knee arthroplasty

Interventions

Part One:The possible doses of hydromorphone around the nerve are as follows: 6-8-10-15-20-25-30-35-40 ug/ml. The initial dose is 10 ug/ml. Subsequently, the patients dose is adjusted using the biased
Part two: hydromorphone combined with ropivacaine group: Continuous caudal block analgesia was administered with 0.25% ropivacaine and ED90 µg/ml hydromorphone, with a total dose of 300 ml. The infusi
Part two: ropivacaine group:Continuous caudal block analgesia was administered with 0.25% ropivacaine, with a total dose of 300ml. The infusion rate was maintained at 4ml/h, the bolus dose was 5ml/ml,

Sponsors

Peking University Shougang Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. ASA classification of I-III; 2. BMI 18-35kg/m^2; 3. Aged 18-80 years; 4. Patients undergoing unilateral total knee arthroplasty under spinal anesthesia and receiving postoperative analgesia; 5. Patients voluntarily participating in the trial, with informed consent signed by the patient one day before surgery

Exclusion criteria

Exclusion criteria: 1. Patients who do not agree or voluntarily withdraw from the study; 2. Patients with a history of knee joint trauma, surgery, malignant tumor, or primary disease of the lower limb nerves or muscles; 3. Patients with severe underlying diseases, such as dysfunction of organs like the heart, liver, lungs, kidneys, and brain, and abnormal blood coagulation; 4. Patients with a history of mental illness; 5. Patients with cognitive impairment who cannot complete analgesia scoring; 6. Patients with contraindications to spinal anesthesia;7. Patients who are allergic to any of the drugs used in this study.

Design outcomes

Primary

MeasureTime frame
The active NRS score 24 hours after the operation;Postoperative resting NRS score;

Secondary

MeasureTime frame
Postoperative opioid consumption;Postoperative opioid-related adverse reactions;Postoperative knee joint function score;

Countries

China

Contacts

Public ContactGuo Zhenggang

Peking University Shougang Hospital

shouganggzg@163.com+86 135 2253 1376

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026